# Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

> **NCT03341520** · PHASE2 · COMPLETED · sponsor: **Heidelberg University** · enrollment: 89 (actual)

## Conditions studied

- Stage II Grade 1 Follicular Lymphoma
- Stage II Grade 2 Follicular Lymphoma
- Stage I Follicular Lymphoma Grade 1
- Stage II Follicular Lymphoma Grade 2

## Interventions

- **DRUG:** Obinutuzumab Injection [Gazyva]
- **RADIATION:** Low dose radiation Therapy (LDRT)

## Key facts

- **NCT ID:** NCT03341520
- **Lead sponsor:** Heidelberg University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-24
- **Primary completion:** 2021-11-11
- **Final completion:** 2024-03-14
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03341520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03341520, "Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03341520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*